Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDQuarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2025 | 2 | -$0.58 | -$0.25 | -$0.48 |
Q2 2025 | 1 | -$0.58 | -$0.25 | -$0.49 |
Q3 2025 | 1 | -$0.56 | -$0.24 | -$0.47 |
Q4 2025 | 1 | -$0.54 | -$0.23 | -$0.45 |
Q1 2026 | 1 | -$0.42 | -$0.18 | -$0.35 |
Q2 2026 | 1 | -$0.43 | -$0.19 | -$0.36 |
Q3 2026 | 1 | -$0.31 | -$0.14 | -$0.26 |
Q4 2026 | 1 | -$0.35 | -$0.15 | -$0.29 |
Recursion Pharmaceuticals, Inc. last posted its earnings results on Wednesday, November 6th, 2024. The company reported $-0.34 earnings per share for the quarter, missing analysts' consensus estimates of $-0.33 by $0.01. The company had revenue of 26.08 M for the quarter and had revenue of 44.58 M for the year. Recursion Pharmaceuticals, Inc. has generated $-2 earnings per share over the last year ($-1.58 diluted earnings per share) and currently has a price-to-earnings ratio of -5.46. Recursion Pharmaceuticals, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 25th, 2025 based on prior year's report dates.
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
11/06/2024 | Q3 2024 | -$0.33 | -$0.34 | -0.01 | $18.72 M | $26.08 M |
08/08/2024 | Q2 2024 | -$0.35 | -$0.40 | -0.05 | $11.96 M | $14.42 M |
05/09/2024 | Q1 2024 | -$0.43 | -$0.39 | 0.04 | $13.79 M | |
02/29/2024 | Q4 2023 | -$0.40 | $10.89 M | |||
11/09/2023 | Q3 2023 | -$0.38 | -$0.43 | -0.05 | $11.24 M | $10.10 M |
08/08/2023 | Q2 2023 | -$0.38 | -$0.38 | 0 | $11.87 M | $11.02 M |
05/08/2023 | Q1 2023 | -$0.34 | -$0.32 | 0.02 | $12.13 M | |
02/27/2023 | Q4 2022 | -$0.15 | -$0.31 | -0.16 | $13.68 M | |
11/08/2022 | Q3 2022 | -$0.36 | -$0.34 | 0.02 | $6.84 M | $13.05 M |
08/09/2022 | Q2 2022 | -$0.35 | -$0.38 | -0.03 | $5.33 M | $7.65 M |
05/10/2022 | Q1 2022 | $0.51 | -$0.33 | -0.84 | $5.30 M | |
03/23/2022 | Q4 2021 | -$0.30 | -$0.38 | -0.08 | $2.50 M | |
11/10/2021 | Q3 2021 | -$0.28 | -$0.28 | 0 | $2.68 M | $2.50 M |
08/13/2021 | Q2 2021 | -$0.23 | -$0.26 | -0.03 | $2.73 M | $2.50 M |
05/12/2021 | Q1 2021 | -$0.18 | $2.50 M | |||
12/31/2020 | Q4 2020 | -$0.15 | $2.55 M | |||
09/29/2020 | Q3 2020 | -$0.14 | $862,000 | |||
06/29/2020 | Q2 2020 | -$0.11 | $186,000 | |||
03/30/2020 | Q1 2020 | -$0.11 | $60,000 |
Recursion Pharmaceuticals, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 25th, 2025 based off last year's report dates.
The conference call for Recursion Pharmaceuticals, Inc.'s latest earnings report can be listened to online.
The conference call transcript for Recursion Pharmaceuticals, Inc.'s latest earnings report can be read online.
Recursion Pharmaceuticals, Inc. (:RXRX) has a recorded annual revenue of $44.58 M.
Recursion Pharmaceuticals, Inc. (:RXRX) has a recorded net income of $44.58 M. Recursion Pharmaceuticals, Inc. has generated $-1.58 earnings per share over the last four quarters.
Recursion Pharmaceuticals, Inc. (:RXRX) has a price-to-earnings ratio of -5.46 and price/earnings-to-growth ratio is -0.98.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED